Hennion & Walsh Asset Management Inc. Makes New $14.78 Million Investment in Indivior PLC $INDV

Hennion & Walsh Asset Management Inc. acquired a new stake in Indivior PLC (NASDAQ:INDV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 360,245 shares of the company’s stock, valued at approximately $14,781,000.

Several other hedge funds have also made changes to their positions in INDV. Yousif Capital Management LLC acquired a new stake in shares of Indivior in the 4th quarter worth $1,137,000. Vanguard Group Inc. raised its holdings in Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Sandro Wealth Management LLC purchased a new position in Indivior during the fourth quarter worth about $1,313,000. State of Alaska Department of Revenue acquired a new stake in Indivior in the fourth quarter valued at about $2,279,000. Finally, Oregon Public Employees Retirement Fund acquired a new stake in Indivior in the fourth quarter valued at about $1,026,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Key Indivior News

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright raised its Indivior earnings forecasts across 2026–2030. The firm lifted its 2026 EPS estimate to $3.66 from $3.08, raised 2027 EPS to $3.83 from $3.34, and increased 2028–2030 estimates to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates also rose to $0.93 for Q3 2026 and $1.07 for Q4, signaling improved expectations for the company’s operating performance. Indivior analyst estimates
• Positive Sentiment: An insider purchased additional shares. Chief Accounting Officer Woodrow Anderson bought 1,500 shares at an average price of $36.28, increasing his direct holdings by 6.09%. Insider buying can be viewed as a modest vote of confidence in the stock’s valuation and outlook. Insider Buying: Indivior CAO Acquires 1,500 Shares
• Neutral Sentiment: Analyst sentiment remains favorable but not uniformly bullish. Indivior has a consensus “Moderate Buy” rating and an average price target of $45.17, while individual recommendations include a $53.00 buy target from Craig Hallum and a reduced—but still “overweight”—$43.00 target from Barclays. Indivior receives Moderate Buy rating
• Negative Sentiment: A law firm is investigating the proposed Supernus acquisition. Kahn Swick & Foti is reviewing whether the transaction’s price and sale process adequately protect Supernus shareholders. Under the proposed deal, Supernus investors would receive 1.5401 Indivior shares per Supernus share. The investigation may add legal and execution uncertainty to the transaction and could raise concerns about potential share issuance and dilution for Indivior investors. Supernus Pharmaceuticals investor alert

Indivior Price Performance

Shares of Indivior stock opened at $38.82 on Friday. Indivior PLC has a 1 year low of $21.83 and a 1 year high of $42.81. The company has a market capitalization of $4.58 billion, a P/E ratio of 13.91 and a beta of 0.86. The business has a 50 day moving average price of $39.28 and a 200 day moving average price of $35.64.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. As a group, research analysts expect that Indivior PLC will post 3.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the topic of several recent analyst reports. Craig Hallum reiterated a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Finally, Barclays decreased their price target on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Indivior currently has an average rating of “Moderate Buy” and an average target price of $45.17.

Insider Activity

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average price of $36.28 per share, for a total transaction of $54,420.00. Following the transaction, the chief accounting officer owned 26,138 shares in the company, valued at $948,286.64. This trade represents a 6.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the transaction, the insider directly owned 209,337 shares of the company’s stock, valued at $8,612,124.18. The trade was a 8.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.